CombiMatrix 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'CombiMatrix Corp	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	11,063,246
Amendment Flag	'false	'
Entity Central Index Key	'0001383183	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

Consolidated_Balance_Sheets_Cu

Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$3,333,000	$12,289,000
Short-term investments	6,765,000	1,747,000
Accounts receivable, net of allowance for doubtful accounts of $310 and $288	1,950,000	1,695,000
Supplies	281,000	171,000
Prepaid expenses and other assets	302,000	128,000
Total current assets	12,631,000	16,030,000
Property and equipment, net	716,000	581,000
Investments in unconsolidated subsidiaries and other	97,000	221,000
Total assets	13,444,000	16,832,000
Current liabilities:	'	'
Accounts payable, accrued expenses and other	1,901,000	1,367,000
Current portion, long-term debt	232,000	168,000
Common stock warrants	'	568,000
Total current liabilities	2,133,000	2,103,000
Capital lease obligations, net of current portion	109,000	65,000
Secured promissory note payable, net of current portion	205,000	'
Total liabilities	2,447,000	2,168,000
Commitments and contingencies (Note 7)	'	'
Stockholders' equity:	'	'
Preferred stock	0	0
Common stock; $0.001 par value; 25 million shares authorized; 11,063,246 and 9,870,838 shares issued and outstanding	11,000	10,000
Additional paid-in capital	96,005,000	95,098,000
Accumulated other comprehensive loss	-4,000	-4,000
Accumulated net losses	-85,015,000	-80,440,000
Total stockholders' equity	10,997,000	14,664,000
Total liabilities and stockholders' equity	13,444,000	16,832,000
Short-term Investments [Member]	'	'
Current assets:	'	'
Short-term investments	6,765,000	1,747,000
Series D Convertible Preferred Stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock	$0	$0

Consolidated_Balance_Sheets_Cu1

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts (in Dollars)	$310	$288
Convertible preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock; shares authorized	5,000,000	5,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	11,063,246	9,870,838
Common stock, shares outstanding	11,063,246	9,870,838
Series D Convertible Preferred Stock [Member]	'	'
Preferred stock; shares authorized	12,000	12,000
Convertible preferred stock, shares issued	0	2,201
Convertible preferred stock, shares outstanding	0	2,201

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Royalties	$35,000	$55,000	$67,000	$80,000
Total revenues	1,941,000	1,500,000	3,763,000	3,111,000
Operating expenses:	'	'	'	'
Cost of services	1,053,000	851,000	2,051,000	1,788,000
Research and development	224,000	177,000	358,000	360,000
Sales and marketing	1,109,000	695,000	1,995,000	1,336,000
General and administrative	2,216,000	1,251,000	3,973,000	2,624,000
Patent amortization and royalties	28,000	66,000	60,000	126,000
Total operating expenses	4,630,000	3,040,000	8,437,000	6,234,000
Operating loss	-2,689,000	-1,540,000	-4,674,000	-3,123,000
Other income (expense):	'	'	'	'
Interest income	24,000	1,000	29,000	1,000
Interest expense	-22,000	-19,000	-38,000	-321,000
Warrant derivative gains	152,000	1,045,000	152,000	2,244,000
Warrant modification charge	-44,000	'	-44,000	'
Total other income (expense	110,000	1,027,000	99,000	1,924,000
Net loss	-2,579,000	-513,000	-4,575,000	-1,199,000
Net loss attributable to common stockholders	-2,579,000	-1,737,000	-4,575,000	-3,086,000
Basic and diluted net (loss) per share (in Dollars per share)	($0.23)	($0.14)	($0.42)	($0.41)
Basic and diluted net loss per share attributable to common stockholders (in Dollars per share)	($0.23)	($0.48)	($0.42)	($1.04)
Basic and diluted weighted average common shares outstanding (in Shares)	11,063,246	3,547,709	10,995,351	2,934,653
Series A Convertible Preferred Stock [Member] | Dividend Declared [Member]	'	'	'	'
Other income (expense):	'	'	'	'
Convertible preferred stock dividends	'	'	'	-246,000
Convertible preferred stock dividends per share (in Dollars per share)	'	'	'	($0.08)
Series C Convertible Preferred Stock [Member] | Dividend Declared [Member]	'	'	'	'
Other income (expense):	'	'	'	'
Convertible preferred stock dividends	'	-11,000	'	-11,000
Series C Convertible Preferred Stock [Member] | Deemed Dividend From Issuing Stock [Member]	'	'	'	'
Other income (expense):	'	'	'	'
Convertible preferred stock dividends	'	-1,213,000	'	-1,213,000
Convertible preferred stock dividends per share (in Dollars per share)	'	($0.34)	'	($0.41)
Series B Convertible Preferred Stock [Member] | Deemed Dividend From Issuing Stock [Member]	'	'	'	'
Other income (expense):	'	'	'	'
Convertible preferred stock dividends	'	'	'	-417,000
Convertible preferred stock dividends per share (in Dollars per share)	'	'	'	($0.14)
Diagnostics Services [Member]	'	'	'	'
Revenues:	'	'	'	'
Diagnostic services	$1,906,000	$1,445,000	$3,696,000	$3,031,000

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net loss	($2,579)	($513)	($4,575)	($1,199)
Unrealized gain on available-for-sale investments	5	'	'	'
Total comprehensive loss	($2,574)	($513)	($4,575)	($1,199)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
			Series B Convertible Preferred Stock and Common Stock [Member]	Series C Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Warrant Modifcations [Member]	Warrant Exercises [Member]
Net loss	($4,575,000)	($1,199,000)	'	'	'	'	'	'
Adjustments to reconcile net loss to net cash flows from operating activities:	'	'	'	'	'	'	'	'
Depreciation and amortization	149,000	481,000	'	'	'	'	'	'
Non-cash stock compensation	266,000	179,000	'	'	'	'	'	'
Warrant derivative gains	-152,000	-2,244,000	'	'	'	'	'	'
Provision for bad debts	214,000	115,000	'	'	'	'	'	'
Warrant modification charge	44,000	'	'	'	'	'	'	'
Accounts receivable	-426,000	-290,000	'	'	'	'	'	'
Supplies, prepaid expenses and other assets	-174,000	-18,000	'	'	'	'	'	'
Accounts payable, accrued expenses and other	608,000	160,000	'	'	'	'	'	'
Net cash flows from operating activities	-4,046,000	-2,816,000	'	'	'	'	'	'
Investing activities:	'	'	'	'	'	'	'	'
Purchases of property and equipment	-134,000	-80,000	'	'	'	'	'	'
Purchase of available-for-sale investments	-5,811,000	'	'	'	'	'	'	'
Sale of available-for-sale investments	750,000	'	'	'	'	'	'	'
Net cash flows from investing activities	-5,195,000	-80,000	'	'	'	'	'	'
Financing activities:	'	'	'	'	'	'	'	'
Proceeds from secured promissory note payable, net of issuance costs	328,000	'	'	'	'	'	'	'
Net proceeds from issuance of stock	'	'	1,768,000	2,314,000	'	'	'	'
Net proceeds from exercise of Series A common stock warrants	256,000	2,399,000	'	'	'	'	'	'
Cost of issuing Series D convertible preferred stock and other	-196,000	'	'	'	'	'	'	'
Payment of accrued financing costs from issuance of Series A convertible preferred stock and secured promissory note payable	'	-106,000	'	'	'	'	'	'
Payments on secured promissory note	-16,000	'	'	'	'	'	'	'
Payments of capital lease obligations	-87,000	-127,000	'	'	'	'	'	'
Net cash flows from financing activities	285,000	6,248,000	'	'	'	'	'	'
Change in cash and cash equivalents	-8,956,000	3,352,000	'	'	'	'	'	'
Cash and cash equivalents, beginning	12,289,000	2,372,000	'	'	'	'	'	'
Cash and cash equivalents, ending	3,333,000	5,724,000	'	'	'	'	'	'
Non-cash financing activities:	'	'	'	'	'	'	'	'
Reclassification of derivative liability to equity	416,000	1,030,000	'	'	'	'	281,000	135,000
Property and equipment purchased under capital lease	88,000	'	'	'	'	'	'	'
Conversion of convertible preferred stock into common stock	'	'	'	'	394,000	303,000	'	'
Deemed dividends from issuing convertible preferred stock	'	'	'	$1,213,000	'	$417,000	'	'

Note_1_Overview_and_Background

Note 1 - Overview and Background	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	1	OVERVIEW AND BACKGROUND
	CombiMatrix Corporation (the “Company,” “we,” “us” and “our”) was originally incorporated in October 1995 as a California corporation and later reincorporated as a Delaware corporation in September 2000. In December 2002, we merged with, and became a wholly owned subsidiary of Acacia Research Corporation (“Acacia”). In August 2007, we split-off from Acacia and became publicly traded on The Nasdaq Stock Market. As a result of the split-off, we ceased to be a subsidiary of, or affiliated with, Acacia.
	Description of the Company
	We provide valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care. We specialize in miscarriage analysis, prenatal and pediatric healthcare, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. We perform genetic testing utilizing a variety of advanced cytogenomic techniques, including microarray, standardized and customized fluorescent in-situ hybridization (“FISH”) and high resolution karyotyping. We emphasize support for healthcare professionals, to ensure data understanding and communication of results to patients. We deliver high-technology driven answers, with a high degree of assistance for the ordering physician and staff.
	We also own a one-third minority interest in Leuchemix, Inc. (“Leuchemix”), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and footnotes required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2013, as reported by us in our Annual Report on Form 10-K filed with the SEC on March 24, 2014. The year-end consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of June 30, 2014, and results of operations and cash flows for the interim periods presented. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the entire year.
	Liquidity and Risks
	We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop new and improve existing commercial diagnostic testing services and related technologies. As of June 30, 2014, we had cash, cash equivalents and short-term investments of $10.1 million and anticipate that our cash and cash equivalent balances will be sufficient to meet our cash requirements for at least the next twelve months. In order for us to ultimately achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities will also cause dilution to our stockholders. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including research projects and personnel, which could jeopardize our future strategic initiatives and business plans.
	Our business operations are also subject to certain risks and uncertainties, including:
		•	market acceptance of our technologies and services;
		•	technological advances that may make our technologies and services obsolete or less competitive;
		•	increases in operating costs, including costs for supplies, personnel and equipment;
		•	variability in third-party reimbursement of our tests;
		•	the availability and cost of capital; and
		•	governmental regulation that may restrict our business.
	Our services are concentrated in a highly competitive market that is characterized by rapid technological advances, frequent changes in customer requirements and evolving regulatory requirements and industry standards. Failure to anticipate or respond adequately to technological advances, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of planned services, could have a material adverse effect on our business and operating results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
	Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.
	Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including Medicare and Medicaid, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of Medicare and Medicaid, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the three and six months ended June 30, 2014 and 2013, net positive revenue adjustments were $121,000, $265,000, $67,000 and $268,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable.
	Clinical trials support services revenue is recognized when the related support services have been delivered to and accepted by the customer. Royalty revenue is recognized in the period when earned.
	Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statement of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.
	Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	●     Level 1:     Observable market inputs such as quoted prices in active markets;
	●     Level 2:      Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	●     Level 3:     Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.
	Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.
	Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. Accounts receivable from two separate commercial insurance carriers of $355,000 and $224,000, respectively, each exceeded 10% of our total accounts receivable balance as of June 30, 2014.
	Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.
	Accounts Receivable and Allowance for Doubtful Accounts. Accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from various payor groups such as commercial insurance companies, healthcare institutions, government payors and individuals. The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables by payor class to assess our allowance at each period end. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible and deducted from the allowance for doubtful accounts after appropriate collection efforts have been exhausted. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor. Collection of receivables due from patients and clients is generally subject to increased credit risk due to credit-worthiness or inability to pay.
	Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the quoted price of our common stock on the date of grant. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):
			Three Months Ended				Six Months Ended
			June 30,				June 30,
			2014		2013		2014		2013
	Cost of services		$	5	$	2	$	9	$	3
	Research and development			-		-		-		-
	Sales and marketing			19		2		30		5
	General and administrative			165		103		227		171
	Total non-cash stock compensation		$	189	$	107	$	266	$	179
	Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:
			Three Months Ended				Six Months Ended
			June 30,				June 30,
			2014		2013		2014		2013
	Common stock options			695,989		625,769		695,989		625,769
	Restricted stock units			380,220		-		380,220		-
	Common stock warrants			7,412,372		2,010,222		7,412,372		2,010,222
	Series B preferred stock convertible into common stock			-		117,232		-		117,232
	Series C preferred stock convertible into common stock			-		839,870		-		839,870
	Excluded potentially dilutive securities			8,488,581		3,593,093		8,488,581		3,593,093
	Segments. We have determined that we operate in one segment for financial reporting purposes.
	Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance regarding revenue recognition, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from generally accepted accounting principles. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional disclosures including those that are qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. The new guidance becomes effective and will be adopted in the first quarter of fiscal year 2017 with early adoption not permitted. We are currently evaluating the appropriate transition method and any further impact of this guidance on our consolidated financial statements and related disclosures.
	In April 2014, the FASB amended guidance to clarify the accounting for disposals of groups of assets and business units. The amendments alter the definition of a discontinued operation to cover only asset disposals that are a strategic shift with a major effect on an entity's operations and finances. The changes should be applied in fiscal years that start on December 15, 2014, or later, but the changes can be applied ahead of the effective date for asset disposals that have not been reported in a set of financial statements. We do not believe adoption of this guidance will have a material impact on our consolidated financial statements or related disclosures.
	In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. Under this guidance, an unrecognized tax benefit, or a portion of an unrecognized tax benefit that exists at the reporting date, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if certain criteria are met. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2013 with early adoption permitted. The adoption of this guidance did not have a material impact on our consolidated financial statements or related disclosures.
	In February 2013, the FASB amended its guidance to require an entity to present the effect of certain significant reclassifications out of accumulated other comprehensive income or loss on the respective line items in net income or loss. The new accounting guidance does not change the items that must be reported in other comprehensive income or loss or when an item of other comprehensive income or loss must be reclassified to net income or loss. The guidance is effective prospectively for fiscal years beginning after December 15, 2012 and we were required to adopt these new provisions during the first quarter of 2013. As the guidance requires additional presentation only, there was no impact to our consolidated financial statements or related disclosures.
	Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation. We reclassified $392,000 and $1.0 million of the derivative warrant gain originally reported for the three and six months ended June 30, 2013, respectively, to additional paid-in capital for the estimated fair value of warrants exercised during these periods.  As a result of these reclassifications, the net loss and the net loss attributable to common stockholders for the three and six months ended June 30, 2013 reported herein have been increased by these amounts.  These reclassifications had no impact on total stockholders’ equity nor any other balance sheet components as of March 31, 2013 or June 30, 2013, and had no impact on total revenues, total operating expenses, and the operating loss reported for the three and six months ended June 30, 2013.

Note_3_Cash_and_ShortTerm_Inve

Note 3 - Cash and Short-Term Investments	6 Months Ended
	Jun. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents Disclosure [Text Block]	'
	3	CASH AND SHORT-TERM INVESTMENTS
	As of June 30, 2014, we held $10.1 million in cash, cash equivalents and short-term investments, which are reported at fair value. Cash, cash equivalents and short-term investments consisted of the following as of June 30, 2014 and December 31, 2013 (in thousands):
			As of June 30, 2014									As of December 31, 2013
					Unrealized					Fair				Unrealized					Fair
			Cost		Gains		Losses			Value		Cost		Gains		Losses			Value
	Cash and money market securities		$	3,333	$	-	$	-		$	3,333	$	11,290	$	-	$	-		$	11,290
	Government bonds			751		-		-			751		-		-		-			-
	Corporate bonds			1,788		-		-			1,788		-		-		-			-
	Certificates of deposit			4,230		-		(4	)		4,226		2,750		-		(4	)		2,746
			$	10,102	$	-	$	(4	)	$	10,098	$	14,040	$	-	$	(4	)	$	14,036
	Included in cash and cash equivalents		$	3,333	$	-	$	-		$	3,333	$	12,290	$	-	$	(1	)	$	12,289
	Included in short-term investments			6,769		-		(4	)		6,765		1,750		-		(3	)		1,747
			$	10,102	$	-	$	(4	)	$	10,098	$	14,040	$	-	$	(4	)	$	14,036

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	4	FAIR VALUE MEASUREMENTS
	The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at June 30, 2014 and December 31, 2013 and the classification by level of input within the fair value hierarchy defined above (in thousands):
						Fair Value Measurements
	30-Jun-14		Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents		$	2,224		$	2,224	$	-	$	-
	Short-term investments			6,765			2,539		4,226		-
	Cash equivalents		$	8,989		$	4,763	$	4,226	$	-
						Fair Value Measurements
	31-Dec-13		Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents		$	8,263		$	7,264	$	999	$	-
	Short-term investments			1,747			-		1,747		-
	Cash equivalents		$	10,010		$	7,264	$	2,746	$	-
	Liabilities:
	Derivative warrant liability		$	568		$	-	$	-	$	568
	The following table is a reconciliation of financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the six months ended June 30, 2014 (in thousands):
			Derivative
			Warrant
			Liability
	Balance, December 31, 2013		$	568
	Changes in fair value			(152	)
	Reclassifications			(416	)
	Balance, June 30, 2014		$	-
	The fair value of the derivative warrant liability is based on Level 3 inputs. For this liability, we developed our own assumptions that do not have observable inputs or available market data to support the fair value recorded. See Note 6 for further discussion of the derivative warrant liability and for the June 2014 modifications, which resulted in permanent equity classification of the warrant liability as of June 30, 2014.

Note_5_Secured_Promissory_Note

Note 5 - Secured Promissory Note	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	5	SECURED PROMISSORY NOTE
	On May 20, 2014 (“Execution Date”), we executed a secured promissory note (the “Note”) with ACC Investment Ltd. in the amount of $350,000, payable in equal amortized payments over a thirty-six month period (the “Term”) from the Execution Date. The note bears an annual interest rate of 10% and is secured by certain laboratory equipment used in our microarray services business. Legal and other closing costs totaling $22,000 were capitalized with the Note and are being amortized over the Term as interest expense. As of June 30, 2014, the fair value of the Note approximated its carrying value of $312,000, net of unamortized closing costs of $21,000.

Note_6_Stockholders_Equity

Note 6 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	6	STOCKHOLDERS’ EQUITY
	Series A Convertible Preferred Stock and Warrants Financing
	During the fourth quarter of 2012, we issued Series A convertible preferred stock (the “Series A Stock”) and warrants to purchase common stock (the “Series A Warrants”) to certain accredited investors (the “Series A Investors”) for gross proceeds of $2.5 million. During the fourth quarter of 2012 and the first quarter of 2013, all of the Series A convertible preferred stock converted into 1.25 million shares of common stock, and during 2013, 1.2 million shares of common stock were issued from the exercise of the Series A Warrants, leaving Series A Warrants to purchase 292,817 shares of common stock unexercised as of December 31, 2013. During the six months ended June 30, 2014, Series A Investors exercised Series A Warrants to purchase 124,111 shares of our common stock, resulting in proceeds of $256,000 to us.
	Holders of the Series A Stock were entitled to receive accruing dividends at the annual rate of 6%, payable semi-annually. Upon conversion of Series A Stock into common stock, we paid to each holder of Series A Stock converting to common stock, as a “make-whole” payment in common stock, an amount equal to $118 per $1,000 of stated value of Series A Stock so converted, less the aggregate amount of dividends previously paid on such converting Series A Stock. During the first six months of 2013, the Series A Investors converted all of the remaining shares of Series A Stock into 822,421 shares of common stock. In addition, 50,307 shares of common stock were issued to the Series A Investors in payment of the make-whole and accrued dividends related to the Series A Stock conversions. The combination of make-whole and accrued dividends paid in shares of common stock for the six months ended June 30, 2013 was $246,000.
	For as long as the Series A Warrants remain unexercised through their expiration date in April 2018, we may not sell securities at an effective price per share less than $4.91 except for certain exempt issuances, unless waivers from the Series A Investors are obtained. Prior to June 2014, the exercise price of the Series A Warrants and the number of shares of common stock underlying the Series A Warrants were subject to full-ratchet anti-dilution adjustments in the event we issue securities, other than certain excepted issuances, at a price below the then current exercise price of the Series A Warrants. In June 2014, we executed modification agreements (the “Modification”) with the remaining Series A Investors to remove the full-ratchet anti-dilution adjustment provisions as well as the Black-Scholes cash buy-back provisions from the terms of the Series A Warrants, thereby eliminating the requirement for derivative accounting and liability classification for the Series A Warrants as of the Modification date. In consideration for agreeing to these Modifications, we issued additional warrants to the Series A Investors to purchase 25,303 shares of common stock at an exercise price of $2.06 per share and an expiration date in April 2018, which are equivalent to the terms of the existing Series A Warrants as modified by the Modification, but are not subject to any registration rights.
	We account for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to our own stock. Prior to the Modification, the Series A Warrants issued to Series A Investors contained such provisions, thus requiring us to treat them as derivative financial instruments, to be recorded at fair value at issuance and subsequently adjusted to fair value at each reporting date, with the corresponding adjustment reflected as a non-operating credit / charge in the consolidated statement of operations. We valued the Series A Warrants using the Monte-Carlo simulation method using the following assumptions immediately prior to the Modification: (i) closing stock price and Series A Warrant contractual exercise price; (ii) term to expiration commensurate with the individual Series A Warrant terms of 3.8 years; (iii) historical volatilities commensurate with the term of the Series A Warrants of 129.6%; (iv) risk-free interest rates commensurate with the term of the Series A Warrants of 1.2%; and (v) simulated anti-dilution impact assuming various probabilities that we will raise additional capital by issuing equity securities at prices above or below the current contractual Series A Warrant exercise prices during the Series A Warrant terms. The result of this valuation simulation was to value the remaining Series A Warrants held by Series A Investors at $281,000 as of the Modification date. As a result, warrant derivative gains of $152,000 were recognized, and the remaining $281,000 was reclassified to additional paid-in capital. As a result of a similar valuation analysis performed during the first quarter ended March 31, 2014, the combined warrant derivative gains recognized in our consolidated statements of operations and the amount of warrant derivative liabilities reclassified to stockholders’ equity resulting from Series A Warrant exercises for the six months ended June 30, 2014 was $152,000 and $416,000, respectively. The additional Series A Warrants to purchase 25,303 shares of common stock given to Series A Investors as consideration for agreeing to the Modification were valued using the Black-Scholes valuation model, using the following assumptions as of the Modification: (i) closing stock price and Series A Warrant contractual exercise price; (ii) term to expiration commensurate with the individual Series A Warrant terms of 3.8 years; (iii) historical volatility commensurate with the term of the Series A Warrants of 129.6%; and (iv) risk-free interest rates commensurate with the term of the Series A Warrants of 1.2%. The resulting valuation of $44,000 was recognized as a non-operating charge in our consolidated statements of operations for the three and six months ended June 30, 2014.
	We valued the Series A Warrants using the Monte-Carlo simulation method using the following assumptions at June 30, 2013: (i) closing stock price and Series A Warrant contractual exercise price; (ii) term to expiration commensurate with the remaining Series A Warrant terms of 4.7 years; (iii) historical volatilities commensurate with the term of the remaining Series A Warrants of 120.5%; (iv) risk-free interest rates commensurate with the term of the remaining Series A Warrants of 1.3%; and (v) simulated anti-dilution impact assuming various probabilities that we will raise additional capital by issuing equity securities at prices above or below the current contractual Series A Warrant exercise price during the Series A Warrant terms. The result of these valuation simulations was to value the remaining Series A Warrants at $1.2 million, which was $1.4 million below their carrying value as of March 31, 2013. As a result, we recognized a $1.0 million non-operating, warrant derivative gain in our consolidated statement of operations for the three months ended June 30, 2013, whereas warrant derivative liabilities from Series A Warrant exercises in the amount of $392,000 were reclassified to stockholders’ equity. As a result of a similar valuation analysis performed during the first quarter ended March 31, 2013, the combined warrant derivative gains recognized in our consolidated statements of operations and the amount of warrant derivative liabilities reclassified to stockholders’ equity resulting from Series A Warrant exercises for the six months ended June 30, 2013 was $2.2 million and $1.0 million, respectively.
	Amortization of the deferred offering-related costs allocated to the Series A Warrants was $280,000 during the six-month period ended June 30, 2013, and was recognized as a component of interest expense.
	Series B Convertible Preferred Stock Financing
	On March 19, 2013, we entered into a securities purchase agreement (the “Series B Purchase Agreement”) with an existing institutional investor (the “Series B Investor”) to purchase 130,000 shares of common stock at a price of $3.05 per share and approximately 1,610.4 units consisting of, in the aggregate, Series B 6% convertible preferred stock (the “Series B Stock”) and warrants to purchase up to 275,000 shares of common stock at an exercise price of $3.49 per share (the “Series B Warrants”) in a registered direct offering (the “Series B Financing”) of securities sold off of our existing shelf registration statement on Form S-3 (File No. 333-176372). The Series B Financing closed on March 20, 2013 (the “Series B Closing”). The Series B Stock and Series B Warrants were sold in multiples of fixed combinations, with each fixed combination consisting of one share of Series B Stock and a Series B Warrant to purchase approximately 171 shares of common stock. Each fixed combination of Series B Stock and Series B Warrants was sold at a price of $1,000. The Series B Stock was initially convertible into an aggregate of 528,000 shares of common stock at an initial conversion price of $3.05 per share. During 2013, the Series B Investor converted all of the Series B Stock into common stock.
	The Series B Warrants were not exercisable for six months from the Series B Closing, and the Series B Stock accrued dividends at an annual rate of 6% beginning six months after the Series B Closing, assuming the Series B Stock had not been converted by that time. Upon the Series B Closing, we received proceeds of $1.8 million, net of placement agent fees and other related paid and accrued costs. Given that the effective conversion price of the Series B Stock was below the closing market price of our common stock at the time of the Series B Closing, we recognized a beneficial conversion feature in the amount of $417,000. Since the Series B Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings.
	The Series B Warrants have a 5½ year term as well as a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series B Warrants, and were not exercisable for the first six months following issuance. The Series B Warrants are not subject to price anti-dilution protection. We also agreed with the Series B Investor pursuant to the Series B Purchase Agreement that, except under certain permitted circumstances, until the time that less than 7.5% of the Series B Warrants remain outstanding, neither we nor our subsidiaries shall issue, or enter into any agreement to issue, common stock or equivalents thereof at a price below the exercise price of the Series B Warrants.
	Series C Convertible Preferred Stock Financing
	On May 3, 2013, we entered into a securities purchase agreement (the “Series C Purchase Agreement”) with certain accredited investors (the “Series C Investors”), pursuant to which we sold and issued 1,200 shares of our newly created Series C 6% convertible preferred stock (the “Series C Stock”) to the Series C Investors at a purchase price of $1,000 per share in an initial closing that occurred on May 6, 2013 (the “Series C First Closing”) and sold and issued 1,200 additional shares of Series C Stock to the Series C Investors on June 28, 2013 at a purchase price of $1,000 per share after stockholder approval was obtained on June 27, 2013 (the “Series C Second Closing”) (combined, the “Series C Financing”). After certain offering-related costs paid, the net proceeds from the Series C Financing was approximately $2.2 million.
	As a result of the Series C Second Closing, the conversion price for the Series C Stock was set to $2.85759 per share, or the equivalent of 839,870 shares of common stock issuable upon conversion of all Series C Stock. The Series C Stock was entitled to 6% annual dividends, and accrued dividends were payable semi-annually, and also on the date of conversion of any Series C Stock, in cash or, subject to certain conditions and at our election, in shares of common stock. If the dividends were paid in shares of common stock, the number of shares of common stock comprising the dividend on each share of Series C Stock was valued at a 20% discount to the average of the daily volume weighted average price for the five-day trading period immediately prior to the dividend payment date. Given that the effective conversion price of the Series C Stock was below the closing market price of our common stock at the time of both of the Series C closings, we recognized beneficial conversion features in the amount of $1.2 million, which were limited to and reduced the net proceeds allocated to the Series C Stock. Since the Series C Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings. During the remainder of 2013, the Series C Investors converted all 2,400 shares of Series C stock into 839,864 shares of common stock.
	In addition to the issuance of the Series C Stock, we issued warrants at the Series C First Closing to purchase 491,803 shares of our common stock with an exercise price of $3.77 per share and at the Series C Second Closing, we issued additional warrants to purchase 491,803 shares of our common stock with an exercise price of $3.55 per share (collectively, the “Series C Warrants”). The Series C Warrants have a 5½ year term, were not exercisable for the first six months following issuance and include a cash-less exercise provision which is only applicable if the common stock underlying the Series C Warrants is not subject to an effective registration statement or otherwise cannot be sold without restriction pursuant to Rule 144. Until all Series C Investors no longer hold Series C Warrants: (i) we may not sell any variable rate securities except for certain exempt issuances; and (ii) if we enter into a subsequent financing on more favorable terms than the Series C Financing, then the agreements between us and the Series C Investors will be amended to include such more favorable terms. In addition, until 7.5% or less of the Series C Warrants remain unexercised, we may not sell any dilutive securities, except for certain exempt issuances.
	Series D Convertible Preferred Stock Financing
	On December 20, 2013 (the “Series D Closing”), we closed an underwritten public offering (the “Series D Offering”) and issued 12,000 units of securities to investors, with each unit consisting of: (i) one share of Series D preferred stock (“Series D Stock”) convertible into shares of our common stock equal to 1,000 divided by the conversion price of $2.06, which was 72.5% of the consolidated closing bid price of our common stock on the Nasdaq Capital Market on December 16, 2013, the date we executed the underwriting agreement (“UA date”); and (ii) one warrant exercisable for 485.4369 shares of our common stock, at an exercise price per share equal to $3.12 (“Series D Warrants”), which was 110% of the consolidated closing bid price of our common stock on the Nasdaq Capital Market on the UA date. The shares of common stock underlying the Series D Stock and Series D Warrants were registered on Form S-1 (File No. 333-191221), which was declared effective by the SEC on December 16, 2013. The Series D Stock was immediately convertible and the Series D Warrants were immediately exercisable for shares of common stock and have a term of five years. In total, there were 5,825,243 shares of common stock issuable upon conversion of the Series D Stock and up to 5,825,243 shares of common stock issuable upon exercise of the Series D Warrants. The units were sold for a purchase price equal to $1,000 per unit, resulting in gross proceeds of $12 million at the Series D Closing. After certain offering-related costs paid to the underwriters and others at the closing and through June 30, 2014, net proceeds received by us were approximately $10.7 million. As of December 31, 2013, 9,799.3 shares of Series D Stock have converted into 4,756,946 shares of common stock. During the first quarter of 2014, all of the remaining Series D Stock converted into an additional 1,068,297 shares of common stock. Also as a result of the Series D Offering, the exercise price of the then-outstanding Series A Warrants automatically ratcheted down by their terms from their then exercise price of $2.86 per share to an adjusted exercise price of $2.06 per share, and the underlying shares exercisable was automatically increased by 81,910 shares. A registration statement on Form S-3 was filed in order to register these shares as per the terms of our original Series A offering documents.
	Warrants
	Outstanding warrants to purchase common stock are as follows:
			Shares of Common Stock
			Issuable from Warrants
			Outstanding as of
			June 30,		December 31,		Exercise
			2014		2013		Price			Expiration
	Liability-classified warrants:
	Oct-12			-		292,817	$	2.06	-1	Mar-18
	Equity-classified warrants:
	Dec-13			5,825,243		5,825,243	$	3.55		Dec-18
	Jun-13			491,803		491,803	$	3.55		Dec-18
	May-13			491,803		491,803	$	3.77		Nov-18
	Mar-13			275,000		275,000	$	3.49		Sep-18
	Oct-12			194,009		-	$	2.06	-1	Apr-18
	Apr-11			131,047		131,047	$	21.4		Apr-16
	Oct-09			3,000		3,000	$	77.8		Oct-14
	May-09			467		2,967	$	75.00 - $90.00		May 2014 - July 2014
	May-09			-		109,997	$	90		May-14
	Total			7,412,372		7,330,860
	Total - all warrants			7,412,372		7,623,677
	-1	Prior to the anti-dilution adjustments which occurred on March 20, 2013, June 28, 2013 and December 20, 2013, these warrants had an initial exercise price of $9.50 per share. Also, due to the Modification previously discussed, these warrants are no longer liability classified as of June 30, 2014.
	Subsequent to June 30, 2014, the remaining May 2009 warrants listed above expired unexercised.

Note_7_Commitments_and_Conting

Note 7 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	7	COMMITMENTS AND CONTINGENCIES
	Executive Severance
	We provide certain severance benefits such that if an executive officer of CombiMatrix Corporation is terminated for other than cause, death or disability, the executive will receive payments equal to three months’ base salary plus medical and dental benefits. In addition, we have implemented a Restated Executive Change of Control Severance Plan (the “Severance Plan”) that affects certain of our senior management-level employees who are classified as “Section 16 Officers” of the Company.  Pursuant to the Severance Plan, if a participating employee is involuntarily terminated (other than for death, disability or for cause) or resigns for “good reason” (as defined in the Severance Plan) during the two-year period following a “change of control” (as defined in the Severance Plan) of the Company, then, subject to execution of a release of claims against the Company, the employee will be entitled to receive: (i) one-half times annual base salary; (ii) immediate vesting of outstanding compensatory equity awards; and (iii) payment of COBRA premiums for the participating employee and eligible dependents for a pre-determined period of time.  Payment of benefits under the Severance Plan will be limited by provisions contained in Section 409A of the U.S. Internal Revenue Code.  The Severance Plan is administered by a plan administrator, which initially is the Compensation Committee of the Board of Directors.  In order to participate in the Severance Plan, an eligible employee must waive any prior retention or severance agreements.
	Litigation
	In 2002, we entered into a settlement agreement with Nanogen, Inc. (“Nanogen”) to settle all pending litigation between the parties. Pursuant to the terms of the settlement agreement, we agreed to make quarterly payments to Nanogen equal to 12.5% of total sales of products developed by us and our affiliates based on the patents that had been in dispute in the litigation, up to an annual maximum amount of $1.5 million. The minimum quarterly payments under the settlement agreement are $25,000 per quarter until the patents expire in 2018. Royalty expenses recognized under the agreement were $25,000 and $50,000 for the three and six months ended June 30, 2014 and 2013, respectively, and are included in patent amortization and royalties in the accompanying consolidated statements of operations.
	On February 14, 2011, Relator Michael Strathmann (“Strathmann”) served us with a complaint (“the Complaint”) filed in the Superior Court of the State of California for the County of Orange. The Complaint alleges we and our former parent Acacia Research Corporation submitted false and fraudulent insurance claims to National Union Fire Insurance Company under the Directors and Officers Policy issued to Acacia, in connection with a prior lawsuit that was settled with Nanogen, Inc., thereby allegedly violating the California Insurance Fraud Prevention Act, and seeks penalties and unspecified treble damages. On May 4, 2011, the Superior Court dismissed the Complaint by ordering that it be stricken for violation of the California Anti-SLAPP statute, which prevents plaintiffs from filing abusive lawsuits against public policy. On June 15, 2011, Strathmann filed a Notice of Appeal with the California Court of Appeals, appealing the granting of the Motion to Strike. On October 24, 2012, the California Court of Appeals reversed the Superior Court's dismissal, finding that the anti-SLAPP statute was not applicable and remanding the case to the Superior Court. Strathmann filed an Amended Complaint, and we and Acacia filed our Answer to that pleading. Discovery has commenced and concluded. We and Acacia filed a motion for summary judgment to dismiss many, if not all, of the claims on the grounds of, among other things, lack of merit, inapplicability of the Insurance Fraud Prevention Act to tenders of defense under third party policies, statute of limitations, jurisdiction and standing. On April 30, 2014, the court denied the motion, finding there were certain “triable issues of fact.” As a result, trial before the court commenced on June 9, 2014 and has continued through the date of this filing, though the trial is expected to conclude later in August. We continue to vigorously pursue the full defenses of this matter. Nevertheless, there can be no assurance we will be ultimately successful.
	From time to time, we are subject to other claims and legal actions that arise in the ordinary course of business. We believe that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on our financial position, results of operations or cash flows. Any legal costs resulting from claims or legal actions are expensed as incurred.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.
	Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including Medicare and Medicaid, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of Medicare and Medicaid, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the three and six months ended June 30, 2014 and 2013, net positive revenue adjustments were $121,000, $265,000, $67,000 and $268,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable.
	Clinical trials support services revenue is recognized when the related support services have been delivered to and accepted by the customer. Royalty revenue is recognized in the period when earned.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statement of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	●     Level 1:     Observable market inputs such as quoted prices in active markets;
	●     Level 2:      Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	●     Level 3:     Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.
Derivatives, Policy [Policy Text Block]	'
	Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. Accounts receivable from two separate commercial insurance carriers of $355,000 and $224,000, respectively, each exceeded 10% of our total accounts receivable balance as of June 30, 2014.
	Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable and Allowance for Doubtful Accounts. Accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from various payor groups such as commercial insurance companies, healthcare institutions, government payors and individuals. The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables by payor class to assess our allowance at each period end. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible and deducted from the allowance for doubtful accounts after appropriate collection efforts have been exhausted. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor. Collection of receivables due from patients and clients is generally subject to increased credit risk due to credit-worthiness or inability to pay.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the quoted price of our common stock on the date of grant. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Cost of services	$	5	$	2	$	9	$	3
	Research and development		-		-		-		-
	Sales and marketing		19		2		30		5
	General and administrative		165		103		227		171
	Total non-cash stock compensation	$	189	$	107	$	266	$	179
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Common stock options		695,989		625,769		695,989		625,769
	Restricted stock units		380,220		-		380,220		-
	Common stock warrants		7,412,372		2,010,222		7,412,372		2,010,222
	Series B preferred stock convertible into common stock		-		117,232		-		117,232
	Series C preferred stock convertible into common stock		-		839,870		-		839,870
	Excluded potentially dilutive securities		8,488,581		3,593,093		8,488,581		3,593,093
Segment Reporting, Policy [Policy Text Block]	'
	Segments. We have determined that we operate in one segment for financial reporting purposes.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance regarding revenue recognition, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from generally accepted accounting principles. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional disclosures including those that are qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. The new guidance becomes effective and will be adopted in the first quarter of fiscal year 2017 with early adoption not permitted. We are currently evaluating the appropriate transition method and any further impact of this guidance on our consolidated financial statements and related disclosures.
	In April 2014, the FASB amended guidance to clarify the accounting for disposals of groups of assets and business units. The amendments alter the definition of a discontinued operation to cover only asset disposals that are a strategic shift with a major effect on an entity's operations and finances. The changes should be applied in fiscal years that start on December 15, 2014, or later, but the changes can be applied ahead of the effective date for asset disposals that have not been reported in a set of financial statements. We do not believe adoption of this guidance will have a material impact on our consolidated financial statements or related disclosures.
	In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. Under this guidance, an unrecognized tax benefit, or a portion of an unrecognized tax benefit that exists at the reporting date, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if certain criteria are met. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2013 with early adoption permitted. The adoption of this guidance did not have a material impact on our consolidated financial statements or related disclosures.
	In February 2013, the FASB amended its guidance to require an entity to present the effect of certain significant reclassifications out of accumulated other comprehensive income or loss on the respective line items in net income or loss. The new accounting guidance does not change the items that must be reported in other comprehensive income or loss or when an item of other comprehensive income or loss must be reclassified to net income or loss. The guidance is effective prospectively for fiscal years beginning after December 15, 2012 and we were required to adopt these new provisions during the first quarter of 2013. As the guidance requires additional presentation only, there was no impact to our consolidated financial statements or related disclosures.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation. We reclassified $392,000 and $1.0 million of the derivative warrant gain originally reported for the three and six months ended June 30, 2013, respectively, to additional paid-in capital for the estimated fair value of warrants exercised during these periods.  As a result of these reclassifications, the net loss and the net loss attributable to common stockholders for the three and six months ended June 30, 2013 reported herein have been increased by these amounts.  These reclassifications had no impact on total stockholders’ equity nor any other balance sheet components as of March 31, 2013 or June 30, 2013, and had no impact on total revenues, total operating expenses, and the operating loss reported for the three and six months ended June 30, 2013.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Cost of services	$	5	$	2	$	9	$	3
	Research and development		-		-		-		-
	Sales and marketing		19		2		30		5
	General and administrative		165		103		227		171
	Total non-cash stock compensation	$	189	$	107	$	266	$	179
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Common stock options		695,989		625,769		695,989		625,769
	Restricted stock units		380,220		-		380,220		-
	Common stock warrants		7,412,372		2,010,222		7,412,372		2,010,222
	Series B preferred stock convertible into common stock		-		117,232		-		117,232
	Series C preferred stock convertible into common stock		-		839,870		-		839,870
	Excluded potentially dilutive securities		8,488,581		3,593,093		8,488,581		3,593,093

Note_3_Cash_and_ShortTerm_Inve1

Note 3 - Cash and Short-Term Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Cash, Cash Equivalents and Investments [Table Text Block]	'
		As of June 30, 2014									As of December 31, 2013
				Unrealized					Fair				Unrealized					Fair
		Cost		Gains		Losses			Value		Cost		Gains		Losses			Value
	Cash and money market securities	$	3,333	$	-	$	-		$	3,333	$	11,290	$	-	$	-		$	11,290
	Government bonds		751		-		-			751		-		-		-			-
	Corporate bonds		1,788		-		-			1,788		-		-		-			-
	Certificates of deposit		4,230		-		(4	)		4,226		2,750		-		(4	)		2,746
		$	10,102	$	-	$	(4	)	$	10,098	$	14,040	$	-	$	(4	)	$	14,036
	Included in cash and cash equivalents	$	3,333	$	-	$	-		$	3,333	$	12,290	$	-	$	(1	)	$	12,289
	Included in short-term investments		6,769		-		(4	)		6,765		1,750		-		(3	)		1,747
		$	10,102	$	-	$	(4	)	$	10,098	$	14,040	$	-	$	(4	)	$	14,036

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
					Fair Value Measurements
	30-Jun-14	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	2,224		$	2,224	$	-	$	-
	Short-term investments		6,765			2,539		4,226		-
	Cash equivalents	$	8,989		$	4,763	$	4,226	$	-
					Fair Value Measurements
	31-Dec-13	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	8,263		$	7,264	$	999	$	-
	Short-term investments		1,747			-		1,747		-
	Cash equivalents	$	10,010		$	7,264	$	2,746	$	-
	Liabilities:
	Derivative warrant liability	$	568		$	-	$	-	$	568
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
		Derivative
		Warrant
		Liability
	Balance, December 31, 2013	$	568
	Changes in fair value		(152	)
	Reclassifications		(416	)
	Balance, June 30, 2014	$	-

Note_6_Stockholders_Equity_Tab

Note 6 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Shares of Common Stock
		Issuable from Warrants
		Outstanding as of
		June 30,		December 31,		Exercise
		2014		2013		Price			Expiration
	Liability-classified warrants:
	Oct-12		-		292,817	$	2.06	-1	Mar-18
	Equity-classified warrants:
	Dec-13		5,825,243		5,825,243	$	3.55		Dec-18
	Jun-13		491,803		491,803	$	3.55		Dec-18
	May-13		491,803		491,803	$	3.77		Nov-18
	Mar-13		275,000		275,000	$	3.49		Sep-18
	Oct-12		194,009		-	$	2.06	-1	Apr-18
	Apr-11		131,047		131,047	$	21.4		Apr-16
	Oct-09		3,000		3,000	$	77.8		Oct-14
	May-09		467		2,967	$	75.00 - $90.00		May 2014 - July 2014
	May-09		-		109,997	$	90		May-14
	Total		7,412,372		7,330,860
	Total - all warrants		7,412,372		7,623,677

Note_1_Overview_and_Background1

Note 1 - Overview and Background (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Disclosure Text Block [Abstract]	'	'
Cash, Cash Equivalents, and Short-term Investments	$10,102	$14,040

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

From Commercial Insurance Carrier 1 [Member]

From Commercial Insurance Carrier 2 [Member]

Restricted Stock Units (RSUs) [Member]

Derivative Warrant Gain to APIC [Member]

Derivative Warrant Gain to APIC [Member]

Accounts Receivable [Member]

Minimum [Member]

Maximum [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Equity Method Investment, Ownership Percentage

'

'

'

'

'

'

'

'

'

'

20.00%

50.00%

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

20.00%

'

20.00%

'

'

'

'

'

'

'

'

'

Net Revenue Adjustments

$121,000

$265,000

$67,000

$268,000

'

'

'

'

'

'

'

'

Fair Value, Concentration of Risk, Accounts Receivable

'

'

'

'

355,000

224,000

'

'

'

'

'

'

Concentration Risk, Percentage

'

'

'

'

'

'

'

'

'

10.00%

'

'

Number of Reportable Segments

'

'

'

'

'

'

1

'

'

'

'

'

Prior Period Reclassification Adjustment

'

'

'

'

'

'

'

$1,000,000

$392,000

'

'

'

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Stock-Based Compensation by Functional Expense Categories (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Stock-based compensation	$189	$107	$266	$179
Cost of Sales [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Stock-based compensation	5	2	9	3
Selling and Marketing Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Stock-based compensation	19	2	30	5
General and Administrative Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Stock-based compensation	$165	$103	$227	$171

Note_2_Summary_of_Significant_4

Note 2 - Summary of Significant Accounting Policies (Details) - Anti-dilutive Securities	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	8,488,581	3,593,093	8,488,581	3,593,093
Equity Option [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	695,989	625,769	695,989	625,769
Restricted Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	380,220	'	380,220	'
Warrant [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	7,412,372	2,010,222	7,412,372	2,010,222
Series B Convertible Preferred Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	'	117,232	'	117,232
Series C Convertible Preferred Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	'	839,870	'	839,870

Note_3_Cash_and_ShortTerm_Inve2

Note 3 - Cash and Short-Term Investments (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Cash and Cash Equivalents [Abstract]	'	'
Cash, Cash Equivalents, and Short-term Investments	$10,102	$14,040

Note_3_Cash_and_ShortTerm_Inve3

Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'	'
Cash and Cash Equivalents, Cost	$10,102	$14,040	'	'
Cash and Cash Equivalents, Unrealized Loss	-4	-4	'	'
Cash and Cash Equivalents, Fair Value	10,098	14,036	'	'
Included in cash and cash equivalents	3,333	12,290	'	'
Included in cash and cash equivalents	'	-1	'	'
Included in cash and cash equivalents	3,333	12,289	5,724	2,372
Included in short-term investments	6,765	1,747	'	'
Short-term Investments [Member]	'	'	'	'
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'	'
Included in short-term investments	6,769	1,750	'	'
Included in short-term investments	-4	-3	'	'
Included in short-term investments	6,765	1,747	'	'
Cash and Money Market Securities [Member]	'	'	'	'
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'	'
Cash and Cash Equivalents, Cost	3,333	11,290	'	'
Cash and Cash Equivalents, Fair Value	3,333	11,290	'	'
Government Securities [Member]	'	'	'	'
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'	'
Cash and Cash Equivalents, Cost	751	'	'	'
Cash and Cash Equivalents, Fair Value	751	'	'	'
Corporate Bonds [Member]	'	'	'	'
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'	'
Cash and Cash Equivalents, Cost	1,788	'	'	'
Cash and Cash Equivalents, Fair Value	1,788	'	'	'
Certificates of Deposit [Member]	'	'	'	'
Note 3 - Cash and Short-Term Investments (Details) - Cash and Short-Term Investments [Line Items]	'	'	'	'
Cash and Cash Equivalents, Cost	4,230	2,750	'	'
Cash and Cash Equivalents, Unrealized Loss	-4	-4	'	'
Cash and Cash Equivalents, Fair Value	$4,226	$2,746	'	'

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) - Financial Assets Measured on Recurring Basis (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets:	'	'
Cash equivalents	$2,224	$8,263
Short-term investments	6,765	1,747
Cash equivalents and Short-term investments	8,989	10,010
Liabilities:	'	'
Derivative warrant liability	'	568
Fair Value, Inputs, Level 1 [Member]	'	'
Assets:	'	'
Cash equivalents	2,224	7,264
Short-term investments	2,539	'
Cash equivalents and Short-term investments	4,763	7,264
Fair Value, Inputs, Level 2 [Member]	'	'
Assets:	'	'
Cash equivalents	'	999
Short-term investments	4,226	1,747
Cash equivalents and Short-term investments	4,226	2,746
Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities:	'	'
Derivative warrant liability	'	$568

Note_4_Fair_Value_Measurements3

Note 4 - Fair Value Measurements (Details) - Financial Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Financial Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs [Abstract]	'
Balance	$568
Changes in fair value	-152
Reclassifications	($416)

Note_5_Secured_Promissory_Note1

Note 5 - Secured Promissory Note (Details) (USD $)	3 Months Ended
	Jun. 30, 2014
Note 5 - Secured Promissory Note (Details) [Line Items]	'
Secured Debt	$312,000
Secured Debt [Member]	'
Note 5 - Secured Promissory Note (Details) [Line Items]	'
Debt Instrument, Face Amount	350,000
Debt Instrument, Term	'36 months
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Issuance Cost	22,000
Deferred Finance Costs, Net	$21,000

Note_6_Stockholders_Equity_Det

Note 6 - Stockholders' Equity (Details) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

Mar. 19, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2013

Mar. 31, 2013

Jun. 30, 2014

Mar. 19, 2013

Mar. 19, 2013

Mar. 19, 2013

3-May-13

Jun. 28, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2013

Mar. 19, 2013

Mar. 19, 2013

Mar. 19, 2013

Jun. 28, 2013

3-May-13

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Purchase Agreement [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series C Warrant [Member]

Series C Warrant [Member]

Series D Warrant [Member]

Amortization of Deferred Offering Costs [Member]

Net [Member]

Series A Warrants [Member]

Net of Offering Costs [Member]

Before Adjustment [Member]

Minimum [Member]

Minimum [Member]

Fixed Combination [Member]

Maximum [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)

'

'

'

'

'

'

'

$2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Converted

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

2,400

'

'

9,799.30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Warrant Exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

124,111

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

485.4369

'

485.4369

'

25,303

25,303

'

25,303

'

292,817

81,910

'

'

171

275,000

'

491,803

491,803

'

'

'

Proceeds from Warrant Exercises (in Dollars)

'

'

'

256,000

2,399,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

256,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

'

'

6.00%

'

'

'

'

6.00%

6.00%

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Make Whole Payment, Per Share (in Dollars per share)

'

$118

'

$118

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Stated Value (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Convertible Securities

528,000

'

'

'

'

'

'

'

'

822,421

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Dividends, Shares

'

'

'

'

'

'

'

'

'

50,307

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends, Preferred Stock (in Dollars)

'

'

'

'

'

'

'

'

'

246,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.91

$1,000

'

'

'

'

'

'

'

Warrants Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,303

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

'

'

'

'

$9.50

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.12

'

$3.12

$2.86

$2.06

$2.06

'

$2.06

'

'

$2.06

'

'

$3.05

$3.49

'

$3.55

$3.77

'

'

'

Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years 255 days

'

'

'3 years 292 days

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

129.60%

120.50%

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.20%

1.30%

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding (in Dollars)

'

'

'

'

'

568,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

281,000

281,000

1,200,000

281,000

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, Gain on Derivative (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

152,000

1,000,000

152,000

2,200,000

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Liability Reclassified to Stockholders Equity (in Dollars)

'

'

'

416,000

1,030,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

281,000

392,000

416,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Adjustment of Warrants (in Dollars)

'

44,000

'

44,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense (in Dollars)

'

22,000

19,000

38,000

321,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

280,000

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

130,000

'

1,610.40

1,200

1,200

'

'

'

'

'

12,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.05

$3.05

'

'

'

'

'

$1,000

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Convertible Preferred Stock (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

1,800,000

'

'

2,200,000

'

2,314,000

10,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,000,000

Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

$417,000

'

'

$1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

Warrant Agreement, Percentage of Warrants Outstanding Threshold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.50%

7.50%

'

'

'

'

Convertible Preferred Stock, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.86

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

839,870

'

'

'

5,825,243

'

5,825,243

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,825,243

'

'

Fair Value Inputs, Discount Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

839,864

'

'

4,756,946

1,068,297

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.06

'

$2.06

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_6_Stockholders_Equity_Det1

Note 6 - Stockholders' Equity (Details) - Outstanding Warrants (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	7,412,372	7,623,677	'
Exercise Price (in Dollars per share)	'	'	$9.50
Liability-classified Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	'	292,817	'
Exercise Price (in Dollars per share)	2.06	'	'
December 2013 [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	5,825,243	5,825,243	'
Exercise Price (in Dollars per share)	3.55	'	'
June 2013 [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	491,803	491,803	'
Exercise Price (in Dollars per share)	3.55	'	'
May 2013 [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	491,803	491,803	'
Exercise Price (in Dollars per share)	3.77	'	'
March 2013 [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	275,000	275,000	'
Exercise Price (in Dollars per share)	3.49	'	'
October 2012 [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	194,009	'	'
Exercise Price (in Dollars per share)	2.06	'	'
April 2011 [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	131,047	131,047	'
Exercise Price (in Dollars per share)	21.4	'	'
October 2009 [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	3,000	3,000	'
Exercise Price (in Dollars per share)	77.8	'	'
May 2009 [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	467	2,967	'
May 2009 [Member] | Minimum [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Exercise Price (in Dollars per share)	75	'	'
May 2009 [Member] | Maximum [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Exercise Price (in Dollars per share)	90	'	'
May 2009 II [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	'	109,997	'
Exercise Price (in Dollars per share)	90	'	'
Equity-classified Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Shares of Common Stock Issuable From Warrants Outstanding	7,412,372	7,330,860	'

Note_7_Commitments_and_Conting1

Note 7 - Commitments and Contingencies (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Litigation Settlement Percentage	12.50%	'	12.50%	'
Maximum Annual Litigation Payment	$1,500,000	'	$1,500,000	'
Minimum Quarterly Litigation Payment	25,000	'	25,000	'
Royalty Expense	$25,000	$25,000	$50,000	$50,000